Breaking News

Wednesday
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
On The Fly
Fly Intel: After-Hours Movers » 18:48
08/05/20
08/05
18:48
08/05/20
18:48
ARLO

Arlo Technologies

$4.97 /

-0.21 (-4.05%)

, BFAM

Bright Horizons

$113.00 /

+1.59 (+1.43%)

, APPS

Digital Turbine

$16.29 /

+0.76 (+4.89%)

, OTRK

Ontrak

$39.36 /

+3.36 (+9.33%)

, PBPB

Potbelly

$3.17 /

-0.14 (-4.23%)

, GMED

Globus Medical

$50.82 /

+2.06 (+4.22%)

, HUBS

HubSpot

$237.01 /

+7.31 (+3.18%)

, MRCC

Monroe Capital

$6.24 /

+0.02 (+0.32%)

, NUS

Nu Skin

$47.39 /

+1.37 (+2.98%)

, ZNGA

Zynga

$10.04 /

-0.16 (-1.57%)

, TRMB

Trimble

$45.92 /

+0.85 (+1.89%)

, AVCT

AVCtechnologies

$4.84 /

+0.37 (+8.28%)

, RBBN

Ribbon Communications

$4.75 /

+0.15 (+3.26%)

, AVXL

Anavex

$4.50 /

-0.29 (-6.05%)

, OSUR

OraSure

$19.60 /

+0.31 (+1.61%)

, ADMA

ADMA Biologics

$3.54 /

+0.155 (+4.58%)

, FSLY

Fastly

$108.92 /

-7.26 (-6.25%)

, QUIK

QuickLogic

$4.01 /

-0.025 (-0.62%)

, WDC

Western Digital

$44.45 /

-0.32 (-0.71%)

, ZIXI

Zix

$7.68 /

+0.05 (+0.66%)

, ADT

ADT Inc.

$12.85 /

+0.09 (+0.71%)

, OLN

Olin

$12.13 /

+0.68 (+5.94%)

, IO

Ion Geophysical

$2.88 /

-0.035 (-1.20%)

, LNC

Lincoln National

$39.01 /

+2.52 (+6.91%)

, ROKU

Roku

$165.76 /

-0.57 (-0.34%)

, MET

MetLife

$38.31 /

+1.41 (+3.82%)

Check out this evening's…

Open Full Text

ShowHide Related Items >><<
ZNGA Zynga
$10.04 /

-0.16 (-1.57%)

ZIXI Zix
$7.68 /

+0.05 (+0.66%)

WDC Western Digital
$44.45 /

-0.32 (-0.71%)

TRMB Trimble
$45.92 /

+0.85 (+1.89%)

ROKU Roku
$165.76 /

-0.57 (-0.34%)

RBBN Ribbon Communications
$4.75 /

+0.15 (+3.26%)

PBPB Potbelly
$3.17 /

-0.14 (-4.23%)

OSUR OraSure
$19.60 /

+0.31 (+1.61%)

OLN Olin
$12.13 /

+0.68 (+5.94%)

NUS Nu Skin
$47.39 /

+1.37 (+2.98%)

MRCC Monroe Capital
$6.24 /

+0.02 (+0.32%)

MET MetLife
$38.31 /

+1.41 (+3.82%)

LNC Lincoln National
$39.01 /

+2.52 (+6.91%)

IO Ion Geophysical
$2.88 /

-0.035 (-1.20%)

GMED Globus Medical
$50.82 /

+2.06 (+4.22%)

FSLY Fastly
$108.92 /

-7.26 (-6.25%)

BFAM Bright Horizons
$113.00 /

+1.59 (+1.43%)

AVXL Anavex
$4.50 /

-0.29 (-6.05%)

AVCT AVCtechnologies
$4.84 /

+0.37 (+8.28%)

ARLO Arlo Technologies
$4.97 /

-0.21 (-4.05%)

APPS Digital Turbine
$16.29 /

+0.76 (+4.89%)

ADT ADT Inc.
$12.85 /

+0.09 (+0.71%)

ADMA ADMA Biologics
$3.54 /

+0.155 (+4.58%)

ARLO Arlo Technologies
$4.97 /

-0.21 (-4.05%)

07/29/20
Fly Intel: Top five analyst upgrades
07/29/20 Raymond James
Arlo Technologies upgraded to Outperform from Market Perform at Raymond James
07/29/20 Raymond James
Arlo Technologies upgraded to Outperform from Market Perform at Raymond James
11/12/19
Fly Intel: Top five analyst initiations
BFAM Bright Horizons
$113.00 /

+1.59 (+1.43%)

04/21/20 BMO Capital
Bright Horizons price target raised to $128 from $100 at BMO Capital
04/21/20 Baird
Bright Horizons price target raised to $135 from $95 at Baird
04/21/20 Jefferies
Bright Horizons price target raised to $139 from $112 at Jefferies
04/21/20 BofA
Bright Horizons downgraded to Underperform from Neutral at BofA
APPS Digital Turbine
$16.29 /

+0.76 (+4.89%)

08/04/20 B. Riley FBR
Digital Turbine price target raised to $18 from $9.50 at B. Riley FBR
07/07/20 Ladenburg
Digital Turbine downgraded to Neutral on valuation at Ladenburg
07/07/20 Ladenburg
Digital Turbine downgraded to Neutral from Buy at Ladenburg
06/25/20 Roth Capital
Digital Turbine price target raised to $13 from $9.50 at Roth Capital
OTRK Ontrak
$39.36 /

+3.36 (+9.33%)

07/16/20 Cowen
Ontrak risk/reward attractive, Cowen starts at Outperform
07/16/20 Cowen
Ontrak initiated with an Outperform at Cowen
PBPB Potbelly
$3.17 /

-0.14 (-4.23%)

12/11/19 Piper Sandler
Potbelly downgraded to Neutral from Overweight at Piper Jaffray
GMED Globus Medical
$50.82 /

+2.06 (+4.22%)

07/21/20 Northland
Globus Medical initiated with a Market Perform at Northland
07/06/20 Piper Sandler
Globus Medical downgraded to Neutral from Overweight at Piper Sandler
05/08/20 SVB Leerink
Globus Medical price target lowered to $56 from $63 at SVB Leerink
03/18/20 BTIG
Globus Medical upgraded to Buy from Neutral at BTIG
HUBS HubSpot
$237.01 /

+7.31 (+3.18%)

08/05/20 Wells Fargo
HubSpot price target raised to $200 from $155 at Wells Fargo
08/04/20 JPMorgan
HubSpot price target raised to $240 from $160 at JPMorgan
08/03/20 Guggenheim
HubSpot price target raised to $260 from $195 at Guggenheim
07/21/20 RBC Capital
HubSpot price target raised to $240 from $185 at RBC Capital
MRCC Monroe Capital
$6.24 /

+0.02 (+0.32%)

04/01/20 Janney Montgomery Scott
Janney Montgomery Scott downgrades four BDCs based on COVID-19 recession
04/01/20 Janney Montgomery Scott
Monroe Capital downgraded to Neutral from Buy at Janney Montgomery Scott
NUS Nu Skin
$47.39 /

+1.37 (+2.98%)

07/02/20
Fly Intel: Top five analyst upgrades
07/02/20 DA Davidson
Nu Skin upgraded to Buy from Neutral at DA Davidson
07/02/20 DA Davidson
Nu Skin upgraded to Buy from Neutral at DA Davidson
07/02/20 Jefferies
Jefferies upgrades Nu Skin to Buy, sees 15%-20% share upside
ZNGA Zynga
$10.04 /

-0.16 (-1.57%)

07/30/20 Berenberg
Activision Blizzard price target raised to $88 from $83 at Berenberg
07/16/20 UBS
Zynga price target raised to $12.50 from $8.30 at UBS
06/22/20 MKM Partners
Snap's new features impressive, says MKM Partners
06/09/20
Fly Intel: Top five analyst upgrades
TRMB Trimble
$45.92 /

+0.85 (+1.89%)

05/29/20 Craig-Hallum
Trimble downgraded to Hold from Buy at Craig-Hallum
05/29/20 Craig-Hallum
Trimble downgraded to Hold from Buy at Craig-Hallum
03/24/20 Needham
Trimble price target lowered to $34 from $48 at Needham
01/09/20 KeyBanc
Trimble initiated with a Sector Weight at KeyBanc
AVCT AVCtechnologies
$4.84 /

+0.37 (+8.28%)

RBBN Ribbon Communications
$4.75 /

+0.15 (+3.26%)

06/15/20 Northland
Northland upgrades Ribbon Communications to Outperform with $6 price target
06/15/20 Northland
Ribbon Communications upgraded to Outperform from Market Perform at Northland
11/14/19 National Securities
Ribbon Communications downgraded to Neutral from Buy at National Securities
10/31/19 Northland
Ribbon Communications downgraded to Market Perform from Outperform at Northland
AVXL Anavex
$4.50 /

-0.29 (-6.05%)

03/16/20
Fly Intel: Top five analyst initiations
03/16/20 H.C. Wainwright
Anavex initiated with a Buy at H.C. Wainwright
02/27/20
Fly Intel: Top five analyst initiations
02/27/20 Cantor Fitzgerald
Anavex initiated with an Overweight and $11 target at Cantor Fitzgerald
OSUR OraSure
$19.60 /

+0.31 (+1.61%)

06/25/20 Lake Street
OraSure initiated with a Buy at Lake Street
04/21/20 Stephens
OraSure resumed with an Equal Weight at Stephens
ADMA ADMA Biologics
$3.54 /

+0.155 (+4.58%)

05/26/20 Maxim
ADMA Biologics' use of plasma is 'oldest trick in pandemic playbook', says Maxim
05/07/20 Oppenheimer
ADMA Biologics price target lowered to $7 from $14 at Oppenheimer
03/16/20 H.C. Wainwright
ADMA Biologics price target lowered to $12 from $14 at H.C. Wainwright
08/12/19 Dawson James
ADMA Biologics downgraded to Neutral from Buy at Dawson James
FSLY Fastly
$108.92 /

-7.26 (-6.25%)

07/17/20 William Blair
William Blair starts Cloudflare at Outperform, says warrants premium
07/10/20
Fly Intel: Top five analyst downgrades
07/10/20 Craig-Hallum
Fastly downgraded to Hold from Buy at Craig-Hallum
07/10/20 BofA
Fastly double-downgraded to Underperform from Buy at BofA
QUIK QuickLogic
$4.01 /

-0.025 (-0.62%)

02/13/20 Craig-Hallum
QuickLogic price target lowered to $8.50 from $14 at Craig-Hallum
01/13/20 Roth Capital
QuickLogic price target raised to $8.50 from 35c at Roth Capital
01/13/20 Oppenheimer
QuickLogic price target raised to $14 from $1 at Oppenheimer
08/15/19
Fly Intel: Top five analyst initiations
WDC Western Digital
$44.45 /

-0.32 (-0.71%)

08/03/20 Stifel
Western Digital to benefit from data center strength, says Stifel
07/15/20
Fly Intel: Top five analyst initiations
07/14/20 Bernstein
Seagate initiated with a Market Perform at Bernstein
07/14/20 Bernstein
Western Digital initiated with an Outperform at Bernstein
ZIXI Zix
$7.68 /

+0.05 (+0.66%)

06/29/20 Northland
Zix price target raised to $11 from $9 at Northland
03/31/20 Northland
Zix debt covenant concerns unfounded, says Northland
03/27/20 Craig-Hallum
Zix assumed with a Buy at Craig-Hallum
11/08/19 Wedbush
Zix initiated with an Outperform, $10 price target at Wedbush
ADT ADT Inc.
$12.85 /

+0.09 (+0.71%)

08/03/20 Goldman Sachs
ADT Inc. price target raised to $17 from $9 at Goldman Sachs
08/03/20 William Blair
Alarm.com downgraded at William Blair on ADT/Google overhang
08/03/20 William Blair
Alarm.com downgraded to Market Perform from Outperform at William Blair
08/03/20 Morgan Stanley
ADT Inc. price target raised to $17 from $7 at Morgan Stanley
OLN Olin
$12.13 /

+0.68 (+5.94%)

05/21/20 Susquehanna
Olin price target lowered to $17 from $21 at Susquehanna
05/01/20 Vertical Research
Olin downgraded to Hold from Buy at Vertical Research
03/26/20 Truist
Olin price target lowered to $12 from $17 at SunTrust
03/26/20 KeyBanc
Olin initiated with a Sector Weight at KeyBanc on caustic direction uncertainty
IO Ion Geophysical
$2.88 /

-0.035 (-1.20%)

07/22/20
Fly Intel: Top five analyst initiations
07/22/20 H.C. Wainwright
Ion Geophysical initiated with a Buy at H.C. Wainwright
03/09/20 Evercore ISI
ION Geophysical downgraded to Underperform from Outperform at Evercore ISI
LNC Lincoln National
$39.01 /

+2.52 (+6.91%)

07/16/20 Credit Suisse
Lincoln National price target lowered to $41 from $52 at Credit Suisse
04/27/20 Credit Suisse
Lincoln National price target lowered to $52 from $68 at Credit Suisse
04/17/20 Citi
Lincoln National downgraded to Neutral from Buy at Citi
03/20/20 RBC Capital
RBC Capital sees some time before Life Insurance returns to 'normal'
ROKU Roku
$165.76 /

-0.57 (-0.34%)

08/04/20 Rosenblatt
Roku price target raised to $190 from $145 at Rosenblatt
08/03/20 Loop Capital
Roku price target raised to $120 from $90 at Loop Capital
07/28/20 Morgan Stanley
Morgan Stanley lowers near-term, long-term forecasts for Roku
07/20/20 MoffettNathanson
Roku initiated with a Neutral at MoffettNathanson
MET MetLife
$38.31 /

+1.41 (+3.82%)

06/01/20 BofA
MetLife reinstated with a Buy at BofA
05/13/20 JPMorgan
MetLife comments at forum 'fairly positive,' says JPMorgan
05/07/20 JPMorgan
MetLife down as much as sector, which is unwarranted, says JPMorgan
04/27/20 Credit Suisse
MetLife price target lowered to $46 from $60 at Credit Suisse
ZNGA Zynga
$10.04 /

-0.16 (-1.57%)

ZIXI Zix
$7.68 /

+0.05 (+0.66%)

WDC Western Digital
$44.45 /

-0.32 (-0.71%)

TRMB Trimble
$45.92 /

+0.85 (+1.89%)

ROKU Roku
$165.76 /

-0.57 (-0.34%)

RBBN Ribbon Communications
$4.75 /

+0.15 (+3.26%)

QUIK QuickLogic
$4.01 /

-0.025 (-0.62%)

PBPB Potbelly
$3.17 /

-0.14 (-4.23%)

OTRK Ontrak
$39.36 /

+3.36 (+9.33%)

OSUR OraSure
$19.60 /

+0.31 (+1.61%)

OLN Olin
$12.13 /

+0.68 (+5.94%)

NUS Nu Skin
$47.39 /

+1.37 (+2.98%)

MRCC Monroe Capital
$6.24 /

+0.02 (+0.32%)

MET MetLife
$38.31 /

+1.41 (+3.82%)

LNC Lincoln National
$39.01 /

+2.52 (+6.91%)

IO Ion Geophysical
$2.88 /

-0.035 (-1.20%)

HUBS HubSpot
$237.01 /

+7.31 (+3.18%)

GMED Globus Medical
$50.82 /

+2.06 (+4.22%)

FSLY Fastly
$108.92 /

-7.26 (-6.25%)

BFAM Bright Horizons
$113.00 /

+1.59 (+1.43%)

AVXL Anavex
$4.50 /

-0.29 (-6.05%)

ARLO Arlo Technologies
$4.97 /

-0.21 (-4.05%)

APPS Digital Turbine
$16.29 /

+0.76 (+4.89%)

ADT ADT Inc.
$12.85 /

+0.09 (+0.71%)

ADMA ADMA Biologics
$3.54 /

+0.155 (+4.58%)

  • 18
    Jun
  • 03
    Jun
  • 21
    May
  • 17
    Mar
  • 07
    Feb
ZNGA Zynga
$10.04 /

-0.16 (-1.57%)

WDC Western Digital
$44.45 /

-0.32 (-0.71%)

ROKU Roku
$165.76 /

-0.57 (-0.34%)

PBPB Potbelly
$3.17 /

-0.14 (-4.23%)

ZNGA Zynga
$10.04 /

-0.16 (-1.57%)

WDC Western Digital
$44.45 /

-0.32 (-0.71%)

ROKU Roku
$165.76 /

-0.57 (-0.34%)

QUIK QuickLogic
$4.01 /

-0.025 (-0.62%)

PBPB Potbelly
$3.17 /

-0.14 (-4.23%)

OSUR OraSure
$19.60 /

+0.31 (+1.61%)

OLN Olin
$12.13 /

+0.68 (+5.94%)

NUS Nu Skin
$47.39 /

+1.37 (+2.98%)

MET MetLife
$38.31 /

+1.41 (+3.82%)

LNC Lincoln National
$39.01 /

+2.52 (+6.91%)

IO Ion Geophysical
$2.88 /

-0.035 (-1.20%)

HUBS HubSpot
$237.01 /

+7.31 (+3.18%)

FSLY Fastly
$108.92 /

-7.26 (-6.25%)

AVXL Anavex
$4.50 /

-0.29 (-6.05%)

APPS Digital Turbine
$16.29 /

+0.76 (+4.89%)

ADT ADT Inc.
$12.85 /

+0.09 (+0.71%)

ZNGA Zynga
$10.04 /

-0.16 (-1.57%)

WDC Western Digital
$44.45 /

-0.32 (-0.71%)

ROKU Roku
$165.76 /

-0.57 (-0.34%)

OTRK Ontrak
$39.36 /

+3.36 (+9.33%)

MET MetLife
$38.31 /

+1.41 (+3.82%)

LNC Lincoln National
$39.01 /

+2.52 (+6.91%)

FSLY Fastly
$108.92 /

-7.26 (-6.25%)

AVXL Anavex
$4.50 /

-0.29 (-6.05%)

APPS Digital Turbine
$16.29 /

+0.76 (+4.89%)

ADT ADT Inc.
$12.85 /

+0.09 (+0.71%)

Earnings
ADMA Biologics reports Q2 EPS (23c), consensus (16c) » 16:41
08/05/20
08/05
16:41
08/05/20
16:41
ADMA

ADMA Biologics

$3.54 /

+0.155 (+4.58%)

Reports Q2 revenue…

Reports Q2 revenue $7.79M, consensus $10.57M. "The first half of 2020 was marked by several achievements and challenges as we navigate through these unprecedented macro-market conditions," said Adam Grossman, President and Chief Executive Officer of ADMA. "Total revenues for the first half of 2020 increased approximately 78% compared to the same prior year period. While the second quarter 2020 revenues were approximately 19% higher than second quarter 2019 revenues, ADMA, and certain of its third-party vendors, experienced impacts from the global COVID-19 pandemic which resulted in unforeseen supply chain disruptions. These COVID-19 disruptions were primarily related to delays with final product Current Good Manufacturing Practice ("cGMP") release testing by third-party vendors. This means that a few of our production batches were finished on schedule but we were unable to submit for U.S. Food and Drug Administration ("FDA") lot release authorization due to delayed test results.

ShowHide Related Items >><<
ADMA ADMA Biologics
$3.54 /

+0.155 (+4.58%)

ADMA ADMA Biologics
$3.54 /

+0.155 (+4.58%)

05/26/20 Maxim
ADMA Biologics' use of plasma is 'oldest trick in pandemic playbook', says Maxim
05/07/20 Oppenheimer
ADMA Biologics price target lowered to $7 from $14 at Oppenheimer
03/16/20 H.C. Wainwright
ADMA Biologics price target lowered to $12 from $14 at H.C. Wainwright
08/12/19 Dawson James
ADMA Biologics downgraded to Neutral from Buy at Dawson James
ADMA ADMA Biologics
$3.54 /

+0.155 (+4.58%)

  • 07
    Feb
Over a month ago
Hot Stocks
ADMA Biologics commences operations at plasma collection facility, submits BLA » 07:20
07/06/20
07/06
07:20
07/06/20
07:20
ADMA

ADMA Biologics

$2.89 /

+0.03 (+1.05%)

ADMA Biologics announced…

ADMA Biologics announced the commencement of operations and initiation of collections at its newest ADMA BioCenters plasma collection facility located in Knoxville, Tennessee. ADMA also announced that it has submitted a biologics license application, or BLA, to the FDA seeking approval for this second plasma collection center. This new, state-of-the-art plasma collection center features automated registration, collection equipment designed to shorten the donation process, free Wi-Fi wireless network in the donor collection area, individual flat screen TVs with cable at each donor station, and certified staff who put donor comfort and safety first. The FDA regulatory process for obtaining approval for this plasma collection center includes a site inspection and an approximately 12-month BLA review period. As such, ADMA expects to receive an approval decision for this second plasma facility in mid-2021. In the meantime, ADMA is permitted to collect plasma donations at this site, and once FDA approved, it can use the plasma collected for production of its FDA approved immunoglobulin products.

ShowHide Related Items >><<
ADMA ADMA Biologics
$2.89 /

+0.03 (+1.05%)

ADMA ADMA Biologics
$2.89 /

+0.03 (+1.05%)

05/26/20 Maxim
ADMA Biologics' use of plasma is 'oldest trick in pandemic playbook', says Maxim
05/07/20 Oppenheimer
ADMA Biologics price target lowered to $7 from $14 at Oppenheimer
03/16/20 H.C. Wainwright
ADMA Biologics price target lowered to $12 from $14 at H.C. Wainwright
08/12/19 Dawson James
ADMA Biologics downgraded to Neutral from Buy at Dawson James
ADMA ADMA Biologics
$2.89 /

+0.03 (+1.05%)

  • 07
    Feb
Hot Stocks
ADMA Biologics appoints Martha Demski to board of directors » 07:12
06/23/20
06/23
07:12
06/23/20
07:12
ADMA

ADMA Biologics

$2.95 /

+0.065 (+2.26%)

ADMA Biologics announced…

ADMA Biologics announced that the proposed resolution to elect Martha Demski to its Board of Directors was approved at the Company's recent Annual Shareholder Meeting, held June 18, 2020. Demski was SVP and CFO of Ajinomoto Althea.

ShowHide Related Items >><<
ADMA ADMA Biologics
$2.95 /

+0.065 (+2.26%)

ADMA ADMA Biologics
$2.95 /

+0.065 (+2.26%)

05/26/20 Maxim
ADMA Biologics' use of plasma is 'oldest trick in pandemic playbook', says Maxim
05/07/20 Oppenheimer
ADMA Biologics price target lowered to $7 from $14 at Oppenheimer
03/16/20 H.C. Wainwright
ADMA Biologics price target lowered to $12 from $14 at H.C. Wainwright
08/12/19 Dawson James
ADMA Biologics downgraded to Neutral from Buy at Dawson James
ADMA ADMA Biologics
$2.95 /

+0.065 (+2.26%)

Hot Stocks
ADMA rises as 60 Minutes teases segment on 'Promise of Plasma' » 10:12
05/29/20
05/29
10:12
05/29/20
10:12
ADMA

ADMA Biologics

$3.27 /

+0.4 (+13.94%)

On its program airing…

On its program airing Sunday, May 31, CBS News' 60 Minutes will feature a segment titled "The Promise of Plasma," in which Bill Whitaker reports on "how doctors are taking the blood plasma of COVID-19 survivors, and the virus-fighting antibodies in it, to create the life-saving therapy." The Fly notes that on May 21, ADMA Biologics announced it has commenced the collection of convalescent plasma through its wholly-owned subsidiary, ADMA BioCenters Georgia, from individuals who have recovered from COVID-19. "Immune globulin is a plasma-derived medicine that is comprised of polyclonal antibodies and is routinely used for the prevention and treatment of certain infectious diseases. Currently, six producers of immune globulin, including ADMA Biologics, supply products to the US market," the company stated at that time. In early Friday morning trading, ADMA shares are up 31c, or 11%, to $3.18. Reference Link

ShowHide Related Items >><<
ADMA ADMA Biologics
$3.27 /

+0.4 (+13.94%)

ADMA ADMA Biologics
$3.27 /

+0.4 (+13.94%)

05/26/20 Maxim
ADMA Biologics' use of plasma is 'oldest trick in pandemic playbook', says Maxim
05/07/20 Oppenheimer
ADMA Biologics price target lowered to $7 from $14 at Oppenheimer
03/16/20 H.C. Wainwright
ADMA Biologics price target lowered to $12 from $14 at H.C. Wainwright
08/12/19 Dawson James
ADMA Biologics downgraded to Neutral from Buy at Dawson James
ADMA ADMA Biologics
$3.27 /

+0.4 (+13.94%)

Recommendations
ADMA Biologics' use of plasma is 'oldest trick in pandemic playbook', says Maxim » 08:18
05/26/20
05/26
08:18
05/26/20
08:18
ADMA

ADMA Biologics

$2.84 /

-0.065 (-2.24%)

, GILD

Gilead

$73.31 /

-0.17 (-0.23%)

, MRNA

Moderna

$69.00 /

+1.99 (+2.97%)

Maxim analyst Jason…

Maxim analyst Jason McCarthy keeps his Buy rating and $6 price target on ADMA Biologics (ADMA), saying the potential of the company's announced plasma collection to tread COVID-19 has gone relatively unnoticed when compared to Moderna's (MRNA) vaccine efforts and Gilead's (GILD) anti-viral development. The analyst adds that the use of convalescent plasma as the "oldest trick in the pandemic playbook" could be the answer in a world that needs help fast, and sees the use of hyperimmune plasma from patients that have recovered as a potentially simple and powerful approach to treat COVID-19.

ShowHide Related Items >><<
MRNA Moderna
$69.00 /

+1.99 (+2.97%)

GILD Gilead
$73.31 /

-0.17 (-0.23%)

ADMA ADMA Biologics
$2.84 /

-0.065 (-2.24%)

ADMA ADMA Biologics
$2.84 /

-0.065 (-2.24%)

05/07/20 Oppenheimer
ADMA Biologics price target lowered to $7 from $14 at Oppenheimer
03/16/20 H.C. Wainwright
ADMA Biologics price target lowered to $12 from $14 at H.C. Wainwright
08/12/19 Dawson James
ADMA Biologics downgraded to Neutral from Buy at Dawson James
07/09/19 Jefferies
ADMA Biologics shares 'too cheap' given progress, says Jefferies
GILD Gilead
$73.31 /

-0.17 (-0.23%)

05/26/20 Truist
Gilead upgraded to Hold at SunTrust on remdesivir commercial prospects
05/26/20 Truist
Gilead upgraded to Hold from Sell at SunTrust
05/26/20 Piper Sandler
Piper Sandler encouraged by remdesivir results published in NEJM
05/21/20 Piper Sandler
Gilead's filgotinib likely being underestimated by Street, says Piper Sandler
MRNA Moderna
$69.00 /

+1.99 (+2.97%)

05/20/20 Morgan Stanley
Moderna price target raised to $90 from $37 at Morgan Stanley
05/19/20 Piper Sandler
Piper trims Moderna target to $100 on capital raise dilution
05/19/20 BMO Capital
Moderna price target raised to $112 from $83 at BMO Capital
05/19/20 H.C. Wainwright
BioNTech upgraded to Buy from Neutral at H.C. Wainwright
MRNA Moderna
$69.00 /

+1.99 (+2.97%)

GILD Gilead
$73.31 /

-0.17 (-0.23%)

ADMA ADMA Biologics
$2.84 /

-0.065 (-2.24%)

MRNA Moderna
$69.00 /

+1.99 (+2.97%)

GILD Gilead
$73.31 /

-0.17 (-0.23%)

MRNA Moderna
$69.00 /

+1.99 (+2.97%)

GILD Gilead
$73.31 /

-0.17 (-0.23%)

MRNA Moderna
$69.00 /

+1.99 (+2.97%)

GILD Gilead
$73.31 /

-0.17 (-0.23%)

Hot Stocks
ADMA Biologics begins collection of COVID-19 plasma from recovered patients » 07:14
05/21/20
05/21
07:14
05/21/20
07:14
ADMA

ADMA Biologics

$2.76 /

+0.16 (+6.15%)

ADMA Biologics announced…

ADMA Biologics announced it has commenced the collection of convalescent plasma through its wholly-owned subsidiary, ADMA BioCenters Georgia, from individuals who have recovered from COVID-19. ADMA is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. ADMA is seeking US citizens who have recovered from coronavirus or COVID-19, to donate plasma, which can be used to produce an immune globulin to potentially help infected patients with COVID-19. People who have recovered from COVID-19 can have antibodies in their plasma that may be helpful in treating the virus. Immune globulin is a plasma-derived medicine that is comprised of polyclonal antibodies and is routinely used for the prevention and treatment of certain infectious diseases. Currently, six producers of immune globulin, including ADMA Biologics, supply products to the US market.

ShowHide Related Items >><<
ADMA ADMA Biologics
$2.76 /

+0.16 (+6.15%)

ADMA ADMA Biologics
$2.76 /

+0.16 (+6.15%)

05/07/20 Oppenheimer
ADMA Biologics price target lowered to $7 from $14 at Oppenheimer
03/16/20 H.C. Wainwright
ADMA Biologics price target lowered to $12 from $14 at H.C. Wainwright
08/12/19 Dawson James
ADMA Biologics downgraded to Neutral from Buy at Dawson James
07/09/19 Jefferies
ADMA Biologics shares 'too cheap' given progress, says Jefferies
ADMA ADMA Biologics
$2.76 /

+0.16 (+6.15%)

Over a quarter ago
Hot Stocks
ADMA anticipates FDA submissions for increased production of BIVIGAM in 2H20 » 08:58
05/07/20
05/07
08:58
05/07/20
08:58
ADMA

ADMA Biologics

$3.19 /

+0.03 (+0.95%)

ADMA Biologics announced…

ADMA Biologics announced several recent corporate achievements pertaining to its supply chain robustness objectives as established at the beginning of 2020. "We have been very active during these challenging times in executing upon what we believe to be high value-added improvements to our supply chain to enhance robustness, increase capacity and heighten control over the production of our products. These achievements include the successful manufacturing of three BIVIGAM conformance batches at an increased scale of plasma volume, purchase of a new aseptic filling machine and installation, along with our plasma collection center expansion initiatives, all of which are on schedule with our budgeted expectations. These important accomplishments are in-line with our 2020 corporate goals and are designed to enhance shareholder valued by reducing operating costs, improve margins and provide for faster turnaround time in the production cycle of our commercial immunoglobulin products," stated Adam Grossman, President and Chief Executive Officer. "We believe these additional capabilities will also allow us to provide a broader range of high-quality services, both to our existing customers, as well as potential new clients and ultimately provide increased control and independence from vendors and contractors as we grow our Company." The conformance batch production for BIVIGAM is at double the plasma volume of the currently U.S. Food and Drug Administration approved process for the manufacture of immune globulin. There have been no significant changes to the manufacturing process, in-process controls or final release testing other than validating the effectiveness of the ADMA manufacturing process at the larger scale. At the newly increased scale, we observed the same potency and purity of the IG production process as our FDA-approved production process. Upon approval of this manufacturing change, ADMA anticipates it will be in a position to produce double the peak forecasted quantity of BIVIGAM using the same equipment, single-use disposables and same labor force. The Vanrx SA25 Workcell has been installed by many leading biologics and vaccine producers in the U.S. and has been FDA approved numerous times. Once installed, the SA25 Workcell will have the capability of rapidly switching between different container and closure formats enabling aseptic filling in a variety of different fill volumes and presentation sizes. Before the BIVIGAM production scale increase and filling machine can be fully implemented for commercial manufacturing, ADMA must submit an amendment to its Biologics License Application to the FDA. ADMA anticipates submitting applications to the FDA for the increased production scale conformance batches of BIVIGAM and the Vanrx filling machine during the second half of 2020. Both the increased production scale and filling machine initiatives and investments are anticipated to be fully operational and contribute to product supply during 2021.

ShowHide Related Items >><<
ADMA ADMA Biologics
$3.19 /

+0.03 (+0.95%)

05/07/20 Oppenheimer
ADMA Biologics price target lowered to $7 from $14 at Oppenheimer
03/16/20 H.C. Wainwright
ADMA Biologics price target lowered to $12 from $14 at H.C. Wainwright
08/12/19 Dawson James
ADMA Biologics downgraded to Neutral from Buy at Dawson James
07/09/19 Jefferies
ADMA Biologics shares 'too cheap' given progress, says Jefferies
Recommendations
ADMA Biologics price target lowered to $7 from $14 at Oppenheimer » 08:49
05/07/20
05/07
08:49
05/07/20
08:49
ADMA

ADMA Biologics

$3.19 /

+0.03 (+0.95%)

Oppenheimer analyst…

Oppenheimer analyst Leland Gershell lowered the firm's price target on ADMA Biologics to $7 from $14 as he awaits better visibility on its sales trajectory. The analyst keeps an Outperform rating on the shares.

ShowHide Related Items >><<
ADMA ADMA Biologics
$3.19 /

+0.03 (+0.95%)

03/16/20 H.C. Wainwright
ADMA Biologics price target lowered to $12 from $14 at H.C. Wainwright
08/12/19 Dawson James
ADMA Biologics downgraded to Neutral from Buy at Dawson James
07/09/19 Jefferies
ADMA Biologics shares 'too cheap' given progress, says Jefferies
06/04/19 Jefferies
ADMA Biologics initiated with a Buy at Jefferies
Earnings
ADMA Biologics reports Q1 EPS (26c), consensus (12c) » 16:42
05/06/20
05/06
16:42
05/06/20
16:42
ADMA

ADMA Biologics

$3.19 /

+0.03 (+0.95%)

Reports Q1 revenue…

Reports Q1 revenue $10.2M, consensus $10.88M. "During the first quarter of 2020, we invested in our supply-chain robustness strategy and continued to make progress with reinforcing and expanding our commercial infrastructure by building out our salesforce and medical affairs teams, while generating encouraging year-over-year quarterly revenue growth," said Adam Grossman, ADMA's president and CEO. "I am extremely proud of the ADMA Biologics team as they have risen to the challenge of navigating the Company through the COVID-19 pandemic while continuing to provide critical immune globulin (IG) and hyperimmune globulin products that U.S. patients and physicians need. Due to our strong foundation, we believe we are well-positioned to not only weather the current macroeconomic challenges, but to continue to execute on our future growth plans. Most importantly, everyone at ADMA offers our immense gratitude to all of the healthcare personnel, first responders and others working on the front lines during this pandemic."

ShowHide Related Items >><<
ADMA ADMA Biologics
$3.19 /

+0.03 (+0.95%)

03/16/20 H.C. Wainwright
ADMA Biologics price target lowered to $12 from $14 at H.C. Wainwright
08/12/19 Dawson James
ADMA Biologics downgraded to Neutral from Buy at Dawson James
07/09/19 Jefferies
ADMA Biologics shares 'too cheap' given progress, says Jefferies
06/04/19 Jefferies
ADMA Biologics initiated with a Buy at Jefferies

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.